Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMJORFK)

• Drug Name: Beta-funaltrexamine Drug Info
• Synonyms: beta-Funaltrexamine; beta-Fna; Naltrexone fumarate methyl ester; 72782-05-9; CHEMBL473136; CHEBI:81527; 2-Butenoic acid, 4-(((5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl)amino)-4-oxo-, methyl ester, (E)-; Beta Funaltrexamine; Beta-Funeltrexamine; SCHEMBL1240811; GTPL1631; ZINC3995756; PDSP2_001549; PDSP2_000394; BDBM50247803; NCGC00163180-01; LS-47116; C18127; methyl 3-[4-cyclopropylmethyl-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-ylcarbamoyl]-
• Cross-matching ID:
  PubChem CID: 5311018
  ChEBI ID: CHEMBL473136
  CAS Number: CAS 72782-05-9
  TTD Drug ID: D0WT7H

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Cholesterol metabolism	2.27	0.00e+0	44/50 (88%)	APOA2;APOB;APOC2;...
Complement and coagulation cascades	1.99	0.00e+0	76/85 (89.41%)	SERPINA1;A2M;CFB;...
Other types of O-glycan biosynthesis	1.97	0.00e+0	29/47 (61.7%)	GALNT1;ST6GAL1;GALNT7;...
N-Glycan biosynthesis	1.88	6.53e-3	38/50 (76%)	ST6GAL1;ALG8;RPN2;...
Mineral absorption	1.84	5.22e-3	48/60 (80%)	MT1E;TF;MT1HL1;...
Synthesis and degradation of ketone bodies	1.74	2.39e-2	9/10 (90%)	HMGCS2;BDH1;HMGCS1;...
PPAR signaling pathway	1.73	2.05e-2	66/74 (89.19%)	FABP1;APOA2;ACOX2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	1.11uM - 10uM	24H	Hide ▲

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	1.11uM - 10uM	24H	Hide ▲